Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ( ...

A year after the FDA approved the use of AngioDynamics' NanoKnife device for prostate cancer treatment, the magazine lists it ...

By targeting a newly uncovered weakness in prostate cancer cells, this could offer an improved treatment for the disease.

Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...

Prostate cancer is the second most common cancer in men worldwide. The post Docs find new vulnerability that may mean better ...

Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...

South Korea's Hyundai ADM Bio said its new cancer drug under development, Penetrium, may prove effective treating diseases ...